FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2959183144> ?p ?o ?g. }

• W2959183144 endingPage "147" @default.
• W2959183144 startingPage "147" @default.
• W2959183144 abstract "147 Background: Antibiotic therapy (ATB) may impair efficacy of immune checkpoint inhibitors (ICPI) through modulation of gut microbiota. Evidence is however limited to trial participants with non-small cell (NSCLC) and renal cell carcinoma (RCC). In this multi-centre study, we validated the impact of ATB in patients (pts) treated with ICPI in routine practice, irrespective of tumour site. Methods: We analysed a prospective dataset of pts treated with ICPI in 2 centres. We documented timing and duration of ATB administered within 1 month prior to ICPI treatment (pATB) or concurrently (cATB) until ICPI cessation. We evaluated response and overall survival (OS) across ATB+/-. Results: We enrolled 196 pts with NSCLC (n=119), Melanoma (n=38) and other histotypes (n=39). Most pts were male (n=137, 70%) with performance status 0-1 (n=159, 84%) and a median number of 2 metastatic sites (range 0-7). Pts received mostly anti-PD-1/PD-L1 ICPI (n=189, 96%) as first-line metastatic therapy (n=120, 62%). Twenty-nine patients (15%) received pATB with penicillins (n=22, 75%) for ≤7 days (n=26, 89%). Sixty-eight pts (35%) received penicillin-based (n=49, 72%) cATB for ≤7 days (n=39, 88%). Respiratory infections were the commonest indication for both pATB (n=16, 55%) and cATB (n=38, 85%). pATB (p<0.001) but not cATB (p=0.76) was associated with worse OS (26 vs. 2 months, Hazard Ratio 7.4, 95% CI 4.2-12.9) and increased likelihood of primary refractoriness to ICPI (44% vs 81%, p<0.001). pATB consistently worsened OS in NSCLC (26 vs. 2.5 months, p<0.001), melanoma (14 vs 3.9 months, p<0.001) and other tumours (11 vs 1.1 months, p<0.001). In multi-variable analyses pATB (p<0.001, HR 3.4, 95% CI 1.9-6.1) and response to ICPI (p<0.001, HR 8.2, 95% CI 4.0-16.9) predicted for OS independent of histotype, tumour burden, PS. Conclusions: This study suggests pATB to exert an independent detrimental effect on response and survival in unselected pts treated with ICPI in routine clinical practice. Mechanistic studies are urgently required to investigate ATB-mediated alterations of gut microbiota as a determinant of poorer outcome following ICPI treatment." @default.
• W2959183144 created "2019-07-23" @default.
• W2959183144 creator A5009737345 @default.
• W2959183144 creator A5010405819 @default.
• W2959183144 creator A5011112130 @default.
• W2959183144 creator A5013845307 @default.
• W2959183144 creator A5019290079 @default.
• W2959183144 creator A5022521906 @default.
• W2959183144 creator A5029516495 @default.
• W2959183144 creator A5031788009 @default.
• W2959183144 creator A5039375708 @default.
• W2959183144 creator A5040369665 @default.
• W2959183144 creator A5042190195 @default.
• W2959183144 creator A5052980856 @default.
• W2959183144 creator A5058165795 @default.
• W2959183144 creator A5060884831 @default.
• W2959183144 creator A5066769987 @default.
• W2959183144 creator A5071080479 @default.
• W2959183144 creator A5072668884 @default.
• W2959183144 creator A5076754182 @default.
• W2959183144 creator A5083141090 @default.
• W2959183144 creator A5086245354 @default.
• W2959183144 date "2019-03-10" @default.
• W2959183144 modified "2023-09-27" @default.
• W2959183144 title "Antibiotic treatment prior to immune checkpoint inhibitor therapy as a tumor-agnostic predictive correlate of response in routine clinical practice." @default.
• W2959183144 doi "https://doi.org/10.1200/jco.2019.37.8_suppl.147" @default.
• W2959183144 hasPublicationYear "2019" @default.
• W2959183144 type Work @default.
• W2959183144 sameAs 2959183144 @default.
• W2959183144 citedByCount "10" @default.
• W2959183144 countsByYear W29591831442019 @default.
• W2959183144 countsByYear W29591831442020 @default.
• W2959183144 countsByYear W29591831442021 @default.
• W2959183144 countsByYear W29591831442022 @default.
• W2959183144 countsByYear W29591831442023 @default.
• W2959183144 crossrefType "journal-article" @default.
• W2959183144 hasAuthorship W2959183144A5009737345 @default.
• W2959183144 hasAuthorship W2959183144A5010405819 @default.
• W2959183144 hasAuthorship W2959183144A5011112130 @default.
• W2959183144 hasAuthorship W2959183144A5013845307 @default.
• W2959183144 hasAuthorship W2959183144A5019290079 @default.
• W2959183144 hasAuthorship W2959183144A5022521906 @default.
• W2959183144 hasAuthorship W2959183144A5029516495 @default.
• W2959183144 hasAuthorship W2959183144A5031788009 @default.
• W2959183144 hasAuthorship W2959183144A5039375708 @default.
• W2959183144 hasAuthorship W2959183144A5040369665 @default.
• W2959183144 hasAuthorship W2959183144A5042190195 @default.
• W2959183144 hasAuthorship W2959183144A5052980856 @default.
• W2959183144 hasAuthorship W2959183144A5058165795 @default.
• W2959183144 hasAuthorship W2959183144A5060884831 @default.
• W2959183144 hasAuthorship W2959183144A5066769987 @default.
• W2959183144 hasAuthorship W2959183144A5071080479 @default.
• W2959183144 hasAuthorship W2959183144A5072668884 @default.
• W2959183144 hasAuthorship W2959183144A5076754182 @default.
• W2959183144 hasAuthorship W2959183144A5083141090 @default.
• W2959183144 hasAuthorship W2959183144A5086245354 @default.
• W2959183144 hasConcept C121608353 @default.
• W2959183144 hasConcept C126322002 @default.
• W2959183144 hasConcept C143998085 @default.
• W2959183144 hasConcept C207103383 @default.
• W2959183144 hasConcept C2777701055 @default.
• W2959183144 hasConcept C2781433595 @default.
• W2959183144 hasConcept C44249647 @default.
• W2959183144 hasConcept C501593827 @default.
• W2959183144 hasConcept C71924100 @default.
• W2959183144 hasConcept C86803240 @default.
• W2959183144 hasConcept C89423630 @default.
• W2959183144 hasConcept C90924648 @default.
• W2959183144 hasConceptScore W2959183144C121608353 @default.
• W2959183144 hasConceptScore W2959183144C126322002 @default.
• W2959183144 hasConceptScore W2959183144C143998085 @default.
• W2959183144 hasConceptScore W2959183144C207103383 @default.
• W2959183144 hasConceptScore W2959183144C2777701055 @default.
• W2959183144 hasConceptScore W2959183144C2781433595 @default.
• W2959183144 hasConceptScore W2959183144C44249647 @default.
• W2959183144 hasConceptScore W2959183144C501593827 @default.
• W2959183144 hasConceptScore W2959183144C71924100 @default.
• W2959183144 hasConceptScore W2959183144C86803240 @default.
• W2959183144 hasConceptScore W2959183144C89423630 @default.
• W2959183144 hasConceptScore W2959183144C90924648 @default.
• W2959183144 hasIssue "8_suppl" @default.
• W2959183144 hasLocation W29591831441 @default.
• W2959183144 hasOpenAccess W2959183144 @default.
• W2959183144 hasPrimaryLocation W29591831441 @default.
• W2959183144 hasRelatedWork W2316928155 @default.
• W2959183144 hasRelatedWork W2605588408 @default.
• W2959183144 hasRelatedWork W2799572226 @default.
• W2959183144 hasRelatedWork W2995806561 @default.
• W2959183144 hasRelatedWork W3090018062 @default.
• W2959183144 hasRelatedWork W3215044659 @default.
• W2959183144 hasRelatedWork W4283162095 @default.
• W2959183144 hasRelatedWork W4319163597 @default.
• W2959183144 hasRelatedWork W4377100578 @default.
• W2959183144 hasRelatedWork W4386391749 @default.
• W2959183144 hasVolume "37" @default.
• W2959183144 isParatext "false" @default.
• W2959183144 isRetracted "false" @default.
• W2959183144 magId "2959183144" @default.

• next